NIH and Biotech Sector

[James Love <love@cptech.org>]

The following web page from the National Cancer Institute (NCI) reports
on a 1996 meeting of the National Cancer Advisory Board.  It provides an
interesting glimps of the relationship between the NIH and the
biotechnology sector.  I recommend reading Dr. Brian Poissant discussion
of intellectual property issues, but several others are also worth
reading.

For example, there is Dr. Wittes, who has worked for NIH on a program
which developed Taxol, then for Bristol-Myers Squibb when it obtained
NIH rights to commercialize Taxol, and is now back at NIH again.  Dr.
Wittes is also the inventor named in a Taxol treatment regime patent NIH
recently licensed to Bristol-Myers Squibb, which BMS used to extend its
US market exclusivity.  (This from my own memory).  Dr. Wittes notes in
his talk that "Of the 77 drugs approved for the treatment of cancer in
the United States by the FDA, NCI data was important for the approval of
about 52 of them."


http://www.nci.nih.gov/extra/deaweb/feb96/ncabmin.htm

              DEPARTMENT OF HEALTH AND HUMAN SERVICES
                       PUBLIC HEALTH SERVICE
                  NATIONAL INSTITUTES OF HEALTH
                    NATIONAL CANCER INSTITUTE
                 NATIONAL CANCER ADVISORY BOARD

                       Summary of Meeting
                      February 27-28, 1996 

                Buidling 31, Conference Room 10
                 National Institutes of Health
                      Bethesda, Maryland

                       ATTENDEES


                    TABLE OF CONTENTS

    [snip]

THE ROLE OF THE BIOTECHNOLOGY INDUSTRY IN
THE NATIONAL CANCER PROGRAM                     Dr. Barbara Rimer and 
                                                Dr. Phil Schein
http://www.nci.nih.gov/extra/deaweb/feb96/ncab13.htm

CONTRIBUTIONS OF THE BIOTECHNOLOGY
INDUSTRY TO THE NATIONAL CANCER PROGRAM          Dr. Fred Craves
http://www.nci.nih.gov/extra/deaweb/feb96/ncab15.htm

REGULATORY POLICY AND REFORM AS IT
AFFECTS THE BIOTECHNOLOGY INDUSTRY              Dr. Alan Goldhammer

INTELLECTUAL PROPERTY ISSUES                    Dr. Brian Poissant
http://www.nci.nih.gov/extra/deaweb/feb96/ncab17.htm

STATE OF THE CAPITAL MARKETS IN SUPPORT 
OF BIOTECHNOLOGY                                Mr. Dennis Purcell
http://www.nci.nih.gov/extra/deaweb/feb96/ncab19.htm

COLLABORATIONS BETWEEN ACADEMIA AND
THE BIOTECHNOLOGY INDUSTRY                      Dr. Mitchell Sayare
http://www.nci.nih.gov/extra/deaweb/feb96/ncab21.htm

COLLABORATION BETWEEN THE NATIONAL
CANCER INSTITUTE AND THE
BIOTECHNOLOGY INDUSTRY                          Dr. Robert Wittes
http://www.nci.nih.gov/extra/deaweb/feb96/ncab23.htm

IMPLICATIONS FOR THE NATIONAL CANCER INSTITUTE  Dr. Tom Mays
http://www.nci.nih.gov/extra/deaweb/feb96/ncab24.htm

 
    [snip]

                                                 

-- 
James Love
Consumer Project on Technology
P.O. Box 19367, Washington, DC 20036
love@cptech.org | http://www.cptech.org
voice 202.387.8030, fax 202.234.5176